Tim Richardson

13PUBLICATIONS
66CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursMedical mycologyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 02, 2026
Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany.

|Jun 17, 2026
Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology-oncology co-management.

|Jun 10, 2026
Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.

|Mar 31, 2026
IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms.

T Richardson, D Schütte, P Gödel

|Mar 24, 2026
Real-world evaluation of belumosudil for chronic ocular graft-versus-host-disease: Efficacy and outcomes.

Leonie Menghesha, Tim Richardson, Jana Knuever

|Feb 13, 2026
Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Jan H Frenking, Christine Riedhammer, Thomas Hielscher

Pageof 3

Frequent Collaborators

4 joint publications

Michael Hallek

3 joint publications

Udo Holtick

3 joint publications

Christoph Scheid

2 joint publications

Daniel Schütte